Related Experiment Video
Updated: Feb 7, 2026
05:54
Spinal Cord Transection In Xenopus laevis Tadpoles
Published on: December 10, 2021
4.5K
Imatinib Mesylate.
1Department of Haematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Centre Freiburg, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany. cornelius.waller@uniklinik-freiburg.de.
Summary
Imatinib mesylate is a targeted therapy for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). While effective and well-tolerated, resistance can develop through BCR-ABL mutations, leading to new drug development.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Imatinib mesylate represents a novel class of small-molecule anticancer agents.
- It selectively targets specific molecular pathways driving cancer, such as BCR-ABL in CML.
Purpose of the Study:
- To review the efficacy and safety of imatinib mesylate in treating chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).
- To discuss the mechanisms of resistance to imatinib and the development of subsequent-generation tyrosine kinase inhibitors.
Main Methods:
- Review of clinical trial data and scientific literature on imatinib mesylate.
- Analysis of molecular mechanisms underlying imatinib resistance.
Main Results:
- Imatinib demonstrates significant clinical activity in CML and GIST patients.
- Treatment is generally well-tolerated, with common side effects including edema and myelosuppression.
- Mechanisms of resistance involve BCR-ABL alterations, including mutations and overexpression.
Conclusions:
- Imatinib is an effective targeted therapy for CML and GIST.
- Understanding resistance mechanisms is crucial for developing next-generation inhibitors like dasatinib and nilotinib.
